SQ109

SQ109 is an orally active small molecule antibiotic developed primarily for the treatment of pulmonary tuberculosis (TB). It is a 1,2-ethylene diamine derivative and an ethambutol analog with a novel mechanism of action distinct from other antibiotics used in TB therapy. Unlike ethambutol, SQ109 inhibits MmpL3 transporter—a transporter involved in mycobacterial cell wall biosynthesis—leading to disruption of cell wall synthesis and bacterial lysis. Additionally, it acts as an uncoupler affecting membrane potential and pH gradients in target organisms. Preclinical studies have shown efficacy against both drug-susceptible and multi-drug-resistant Mycobacterium tuberculosis strains as well as activity against other bacteria such as Helicobacter pylori. Clinical trials have demonstrated safety and tolerability in Phase I/II studies[1][3][5][6][8].

Other names

N-adamantanyl-N'-geranyl-ethylenediamineN-Geranyl-N'-(2-adamantyl)ethane-1,2-diamine